Skip to content

The therapeutic use of cold atmospheric plasma for treatment of light acne papulopustulosa

The therapeutic use of cold atmospheric plasma for treatment of light acne papulopustulosa

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
DRKS
Registry ID
DRKS00032416
Enrollment
40
Registered
2023-08-03
Start date
2023-08-14
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

L70.0

Interventions

Group 1: Acne treatment: Cold astmopheric plasma therapy verum 1/week, facial skin mechanical cleansing 1/week, Differin® Cream 0,1% Adapalen daily diagnostics: fotodocumentation , sebumetry, Visiopo

Sponsors

Dermatologie am Luisenplatz
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to No maximum

Inclusion criteria

Inclusion criteria: -All patients over 18 years of age who are capable of giving consent or patients >13 years of age who are incapable of giving consent, with the consent of their parents, who wish to present themselves and be treated for the diagnosed clinical picture of mild acne papulopustulosa. -The diagnosis has been present for > 6 months -The patient agrees not to treat the affected skin areas in any other way than the intended therapy / or to be treated elsewhere within the framework of the study externally

Exclusion criteria

Exclusion criteria: -Patients under care or incapable of giving consent -The patient is younger than < 13 years -Difficulties in follow-up over the study period until the end of the 4-week follow-up period are foreseeable. -The patient is currently participating in a clinical trial for the same indication. -The patient smokes -The affected region was treated by a doctor/the patient himself/herself within 4 weeks before the start of the study - Women who are planning pregnancy - Hypersensitivity to the active substance adapalene - Cracked, abraded skin, acute dermatitis and eczema - Severe forms of acne vulgaris and secondary forms of acne

Design outcomes

Primary

MeasureTime frame
Reduction of the total inflammatory lesion count (TILC) including papules and pustules Improvement of the IGA Acne Score (Investigator global assessment acne score)

Secondary

MeasureTime frame
Reduction of sebumetry (Reduction of sebum production) Reduction of porphyrin fluorescence signal (Reduction of A. acnes colonization) Reduction of acne QOLI questionare score (Improvement of acne specific life quality)

Countries

Germany

Contacts

Public ContactChristoph Geilen

Dermatologie am Luisenplatz

melvin.bae@charite.de01788878658

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026